Earnings summaries and quarterly performance for Arbutus Biopharma.
Executive leadership at Arbutus Biopharma.
Board of directors at Arbutus Biopharma.
Research analysts who have asked questions during Arbutus Biopharma earnings calls.
RB
Roy Buchanan
Citizens JMP
6 questions for ABUS
Also covers: CDTX, CVAC, DVAX +5 more
Brian Skorney
Robert W. Baird & Co.
3 questions for ABUS
Also covers: CRNX, MIRM, MRNS +6 more
WY
Wing Yip
Unspecified
3 questions for ABUS
Also covers: ACXP, ARCT, DRRX +2 more
YD
Yuchen Ding
H.C. Wainwright & Co.
3 questions for ABUS
Also covers: ARDX, CRNX, RYTM
EA
Ed Arce
WestPark Capital
1 question for ABUS
Also covers: AKBA, ARCT, AUPH +5 more
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for ABUS
Also covers: ARDX, ENTA, GALT +6 more
Recent press releases and 8-K filings for ABUS.
Arbutus Biopharma Corp. Receives Mixed Rulings in Patent Infringement Lawsuit Against Moderna
ABUS
Legal Proceedings
- On February 2, 2026, the U.S. District Court for the District of Delaware issued a mixed ruling in the patent infringement lawsuit filed by Arbutus Biopharma Corp. and Genevant Sciences GmbH against Moderna Inc. regarding Moderna's COVID-19 vaccine, MRNA-1273.
- The court granted Moderna's defense under 28 U.S.C. § 1498(a) for vaccines supplied directly to U.S. Government employees, directing these claims to the Court of Federal Claims.
- Conversely, the court denied Moderna's Section 1498 defense for most vaccine doses, allowing Arbutus's claims regarding these doses to proceed in the current court.
- The court barred Arbutus's doctrine-of-equivalents claims for U.S. Patent Nos. 8,492,359, 9,364,435, and 11,141,378, requiring Arbutus to prove literal infringement for these patents.
- The crucial question of the invalidity of Arbutus's patents will be decided by a jury.
9 hours ago
Arbutus Biopharma Reports EPO Patent Revocation
ABUS
Legal Proceedings
- On January 15, 2026, the Board of Appeal of the European Patent Office (EPO) revoked Arbutus Biopharma Corporation’s European patent EP 2279254.
- The Company disagrees with this verbal decision and intends to file a petition for review by the Enlarged Board of Appeal of the EPO upon receipt of the written decision.
- This decision is likely to affect certain ongoing patent cases brought by the Company and its licensee Genevant Sciences GmbH against Moderna in Switzerland and one case in the Unified Patent Court.
- However, the Company does not expect this decision to impact its patent infringement litigation against Moderna in the United States, Japan, or Canada, or its litigation against Pfizer Inc. and BioNTech SE in the United States, as the EPO decision was based on a standard not applicable in those jurisdictions.
Jan 16, 2026, 12:41 PM
Arbutus Biopharma Provides Update on LNP Patent Litigation Against Moderna and Pfizer/BioNTech
ABUS
Legal Proceedings
- Arbutus Biopharma Corporation (ABUS) is engaged in patent infringement lawsuits against Moderna Therapeutics, Inc., Pfizer Inc., and BioNTech SE, alleging unauthorized use of its patented lipid nanoparticle (LNP) technology in their COVID-19 vaccines.
- Genevant and Arbutus estimate that global sales of Moderna's and Pfizer/BioNTech's COVID-19 vaccines have totaled approximately $145 billion as of September 30, 2025.
- A US jury trial in the Moderna litigation is scheduled for March 2026, with initial ex-US hearings also anticipated in 2026.
- Markman rulings (claim construction) in both the US Moderna and Pfizer/BioNTech cases have been issued and are generally viewed as favorable by Genevant.
Dec 11, 2025, 1:00 PM
Arbutus Biopharma Reports Q3 2025 Financial Results and Provides Corporate Update
ABUS
Earnings
Legal Proceedings
New Projects/Investments
- Arbutus Biopharma reported a net loss of $7.7 million, or $0.04 per basic and diluted common share, for the third quarter of 2025, a reduction from a net loss of $19.7 million, or $0.10 per share, in the same period of 2024.
- The company maintained a strong financial position with cash, cash equivalents, and marketable securities of $93.7 million as of September 30, 2025.
- Additional analysis of imdusiran (AB-729) clinical data showed that 46% of Phase 2a patients met criteria to discontinue all treatment, with 94% of long-term follow-up patients remaining off all treatment for up to 2+ years.
- In LNP litigation, the Moderna U.S. trial is scheduled for March 2026, and a favorable claim construction ruling was issued in September 2025 for the Pfizer-BioNTech litigation.
Nov 13, 2025, 12:31 PM
Arbutus Biopharma Reports Q3 2025 Financial Results and Litigation Updates
ABUS
Earnings
Legal Proceedings
New Projects/Investments
- Arbutus Biopharma reported a net loss of $7.7 million, or $0.04 per basic and diluted common share, for the third quarter of 2025, an improvement from the $19.7 million net loss in the same period of 2024. The company held $93.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
- The company provided updates on its LNP litigation, including a favorable claim construction ruling in the Pfizer-BioNTech lawsuit issued in September 2025 and a U.S. trial against Moderna scheduled for March 2026.
- Additional analysis of imdusiran (AB-729) clinical data showed that 46% of Phase 2a patients met criteria to discontinue all treatment, and 94% of long-term follow-up patients remain off all treatment for up to 2+ years.
Nov 13, 2025, 12:30 PM
Arbutus Biopharma Announces Four Abstracts Accepted for Presentation at AASLD Liver Meeting 2025
ABUS
New Projects/Investments
Product Launch
- Arbutus Biopharma Corporation announced on October 7, 2025, the acceptance of four abstracts for presentation at The Liver Meeting 2025, featuring data for its drug candidates imdusiran and AB-101.
- The AB-101 abstract was notably selected as a Poster of Distinction.
- Clinical data for imdusiran indicated it was safe and well-tolerated and may enhance interferon responsiveness in chronic hepatitis B patients.
- AB-101 demonstrated general tolerability at doses up to 30 mg QD for 28 days, with preliminary data showing dose-related increases in PD-L1 receptor occupancy, reaching 83% mean maximal occupancy at the 30 mg dose.
- To date, eight patients with chronic hepatitis B virus have achieved a functional cure following treatment with imdusiran in combination with other therapies.
Oct 7, 2025, 12:01 PM
Quarterly earnings call transcripts for Arbutus Biopharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more